People

Jenna Hebert holds the source-published role of Investment Director within RA Capital Management’s Healthcare group. The individual directory reports joining in2021; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: University of Pennsylvania, University of Oxford. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Laura Tadvalkar is currently a Managing Director on the Venture Team at RA Capital Management, which she joined in 2020. RA Capital’s own biography confirms her prior Principal role at MP Healthcare Venture Management and earlier consulting at Clarion Healthcare. She completed her Kauffman fellowship at MPH with Jeffrey Moore and Naoya Sato as mentors. Her RA Capital interview describes supporting an MPH portfolio company’s business-development work. She holds a BS in Chemistry from Yale and a PhD in Chemical Biology from Harvard. Her MPH role is historical; the current RA role, portrait and personal financial attributions are preserved. Current source-verified RA affiliation: Laura Tadvalkar holds the source-published role of Managing Director, Venture within RA Capital Management’s Healthcare group. The individual directory reports joining in2020; a precise appointment day is not available. Published academic qualifications: PhD. Universities identified in the own biography: Yale University, Harvard University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Matt Stanton holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: PhD, BS. Universities identified in the own biography: University of North Carolina at Chapel Hill, Virginia Technical University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Biotechnology company builder and chemist formerly leading Peloton Therapeutics, with earlier discovery-chemistry experience at Array BioPharma.

Mikael Dolsten is published by Arbor Biotechnologies as Board Member. Arbor lists this professional background: Former Chief Scientific Officer and President, Worldwide Research, Development and Medical at Pfizer, Inc..

Paul B. Rothman, M. D. Director, Chair of the Quality and Compliance Committee Paul B. Rothman has served as a director of the Company since June 6, 2023 and as Chairman of the Quality and Compliance Committee since June 2024. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa. Dr. Rothman currently serves on the board of directors of Merck and Co. and the King Faisal Specialist Hospital and Research Center in Saudi Arabia. In addition, he consults for several investment firms including RA Capital, Mingxin Capital Growth Fund and ANV Management. Dr. Rothman holds a Bachelor of Science degree in biology from the Massachusetts Institute of Technology and an M.D. from Yale University, and is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Sciences, the American Society for Clinical Investigation, and the Association of American Physicians. Current source-verified RA affiliation: Paul Rothman holds the source-published role of Venture Partner within RA Capital Management’s Raven group. The individual directory reports joining in2025; a precise appointment day is not available. Published academic qualifications: MD. Universities identified in the own biography: Massachusetts Institute of Technology, Yale University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Dementia Discovery Fund partner with prior pharmaceutical business development experience; helped establish the fund and serves on boards of its biotechnology portfolio companies. Laurence Barker is a TRIMTECH non-executive director and SV Health Investors partner focused on the Dementia Discovery Fund. Before joining SV in 2016, he managed venture investments and licensing within GSK business development and worked at biotechnology companies.

SV Health Investors operating partner and Pheno Therapeutics non-executive director; molecular biologist with research leadership experience at Repertoire, Bioverativ and Biogen.

Jeffrey Cummings chairs ALZpath’s Scientific Advisory Board and leads the Chambers-Grundy Center for Transformative Neuroscience at UNLV. His work focuses on Alzheimer’s disease, clinical trials and drug development.

Vikram Sudarsan serves as President and Chief Executive Officer at Engrail Therapeutics, a precision neuroscience drug-development company.

Duc brings over 25 years of drug development experience spanning a broad range of therapeutic areas, including cardiovascular, anti-infective, urology, epigenetics, CNS, reproductive medicine, autoimmune diseases, and oncology. His experience covers the full drug development continuum, from lead optimization through pivotal Phase III clinical development stages. Duc has built this expertise through senior roles in both large pharmaceutical companies, including Sanofi-Aventis, Pfizer, and Lundbeck, and innovative biotech companies such as Preglem (acquired by Gedeon Richter), Arisgen, EspeRare, Prexton Therapeutics (acquired by Lundbeck), Calypso Biotech (acquired by Novartis) and Step Pharma. He has successfully advanced multiple programs from early development through clinical development. Duc graduated from the French Grandes Écoles d’ingénieurs ESPCI with training in Physics, Chemistry, and Biology. He also holds an MSc in organic and bio-organic chemistry from Université Paris VI. ‍

Martin Müller is a Senior Investment Manager at CARMA FUND, joining in October 2023. With a medical background, he conducted cardiac imaging research at Leipzig Heart Center and Harvard Medical School, trained in radiology, and later worked in strategy consulting, private equity advisory and Philips Ventures.

Westley Dang is listed by SOSV as Partner.

Dr. Yves Ribeill, PhD, currently works as a Partner and Entrepreneur in Residence at Argobio Studio in Paris, France. He is a seasoned entrepreneur who founded Scynexis, Inc (NASDAQ: SCYX) and served as its President from 1999 to 2015, as well as its Chief Executive Officer from 1999 to 2015. Prior to his tenure at Scynexis, Inc., he held various positions at Rhone-Poulenc, Aventis, where he spent 20 years of his international career and served as Director of Chemistry for the Anti-Infective Group. Throughout his career, he has played a key role in the development and FDA approval of numerous drugs at Rhone-Poulenc and Scynexis. He has also served on the board of directors for various biotech companies in Europe and the US, and currently chairs the board of Calyxt (NASDAQ:CLXT). Dr. Ribeill holds a Ph.D. in Chemistry from the University of Montpellier (France) and has authored over 26 publications and 17 patents. He is a member of the Scientific Advisory Board of DNDi, and has previously served on the Scientific Advisory Committee of the World Health Organization and the Medicine Malaria Venture in Geneva.

Valentin Tonnel is an investment manager in the Q4 2024 WE Life Sciences roster, joined November 2023 after corporate-finance advisory work supporting strategy and financing. Holds a molecular-biology/genetics master’s degree from Louvain and MIT healthcare-finance professional certificate. The dated public roster does not by itself establish a new employment start day or uninterrupted tenure through October 2026.

Thomas Harth is named on Anaconda Biomed’s current public board of directors. The issuer identifies the affiliation as YSIOS CAPITAL. This confirms the board relationship without establishing a personal investment.

Thierry Laugel appears in Idinvest Partners’ August2020 primary directory as Strategic Advisor. The publisher separately classified this as an external strategic or investment advisory affiliation, rather than full-time operating staff. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

Rémi Droller appears in Idinvest Partners’ August2020 primary directory as Strategic Advisor. The publisher separately classified this as an external strategic or investment advisory affiliation, rather than full-time operating staff. The named historical role is distinguished from the preserved later Eurazeo affiliations. Idinvest became Eurazeo Investment Manager and was subsequently absorbed into Eurazeo Global Investor. Joining and departure days and unpublished prior career or education details are not inferred.

George Garibaldi is a neuroscience drug-development physician and current Synendos Therapeutics Chief Medical Officer. Noema’s2020 issuer release identifies him as its Chief Medical Officer, and Newron’s2026 primary biography confirms that he co-founded Noema. The Noema position is historical and does not replace his existing Synendos role.

Joyce Erony is an Amzak Health managing partner and medical-device investor, previously a Signet Healthcare Partners managing director.

Debra Snowdale is Novocuff’s CFO and is also published as ShiraTronics’ CFO. Her own ShiraTronics biography describes more than twenty years in medical-device finance leadership and advisory work, with experience at ExclusiveCFO, Ernst & Young and Philips Medical Systems.

Life-sciences investor and biotechnology board director, published as a managing partner at Sands Capital.

Evidation Health co-founder identified in Akili’s2022 public-board directory; resigned from Akili’s board July2,2024 at the acquisition. Dated board affiliation is preserved separately from outside advisory roles.

Søren Rask Tange is published as Finance Director by both Heartcore Capital and Sunstone Life Science Ventures. Their own directories link the same individual LinkedIn identity.

Andreas Wallnöfer advises ClavystBio and has held senior Roche research and development positions, including cardiovascular and metabolism leadership. His investing career includes BioMedPartners and Jeito Capital. He holds a pharmacology doctorate from Basel and an executive MBA from IMD.

Timothy Lu is a scientific co-founder, board member and scientific advisory co-chair of Engine Biosciences, as published in its April2026 directory. His synthetic-biology research at MIT helped establish the technology; he also co-founded Senti Biosciences and several other biotechnology companies. Goodman Capital’s archived May2019 primary team directory additionally identifies Timothy Lu as Advisor (historical published affiliation). This Singapore firm invested its principals’ and families’ capital; the role is source-qualified historical and does not imply a currently held appointment or personal cash investment.

Partner at Invivo Partners and chairwoman of Eclova Therapeutics. She holds a PhD in Biotechnology and worked in oncology gene therapy and technology transfer at Vall d’Hebron Research Institute before entering venture capital.